晚期前列腺癌基因组的种族差异
本研究汇总四个转移性去势抵抗性前列腺癌(mCRPC)肿瘤活检队列的基因组与临床病理数据,评估不同种族患者的转录组、突变及临床差异。在445例mCRPC患者中,非洲裔美国患者肿瘤的MYC通路基因表达较高,IFN-γ、IL-6/JAK/STAT3和炎症通路基因表达较低;TMPRSS2:ERG基因融合在欧洲裔美国患者中更常见(41% vs. 11%,P = 0.015);各种族间总生存无差异。
要点
- 非洲裔美国mCRPC患者肿瘤MYC通路基因表达较高(FDR q = 0.03)。
- 非洲裔美国患者IFN-γ、IL-6/JAK/STAT3和炎症通路基因表达较低(FDR q < 0.001)。
- TMPRSS2:ERG融合欧洲裔美国 vs. 非洲裔美国为41% vs. 11%(P = 0.015),各种族总生存无差异。
核心结论
- 尽管临床结局相似,非洲裔美国患者的mCRPC肿瘤呈现独特的肿瘤生物学特征。
- 观察到前列腺癌驱动基因通路(包括IFN-γ和JAK/STAT等潜在可临床干预通路)表达及DNA改变(包括TMPRSS2:ERG基因融合)的种族差异。
- 研究结果强调未来基因组分析和临床试验中种族多样性的重要性。
研究设计与样本
- 研究获取并汇总四个mCRPC肿瘤活检队列的基因组与临床病理数据。
- 采用基因集富集分析评估不同患者种族间基因表达的通路水平差异。
- 比较不同种族组间已知前列腺癌驱动基因的DNA改变频率及临床结局。
- 队列共纳入445例mCRPC男性患者。
主要发现
- 非洲裔美国患者(N = 26)肿瘤MYC通路基因表达高于欧洲裔美国患者(FDR q = 0.03)。
- 非洲裔美国患者IFN-γ、IL-6/JAK/STAT3和炎症通路基因表达低于欧洲裔美国患者(FDR q < 0.001)。
- TMPRSS2:ERG基因融合在欧洲裔美国患者中较非洲裔美国患者更常见(41% vs. 11%,P = 0.015)。
- 亚洲患者(N = 9)及其他种族组在队列中所占比例很小。
- 各种族组间总生存未见差异。
局限性
- 亚洲患者(N = 9)及其他种族组在队列中所占比例很小。
- 研究结论指出需在未来基因组分析和临床试验中重视种族多样性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Racial differences in metastatic castration-resistant prostate cancer (mCRPC) genomes have not yet been fully studied. We aimed to investigate transcriptomic, mutational, and clinical differences by race in a large multi-institutional cohort of men with mCRPC. METHODS: Genomic and clinicopathologic data from four mCRPC tumor biopsy cohorts were obtained and aggregated. Gene set enrichment analyses were performed to assess pathway-level differences in gene expression by patient race. DNA alteration frequencies of known prostate cancer driver genes and clinical outcomes were compared across racial groups. RESULTS: In our cohort of 445 men with mCRPC, tumors from African American patients (N = 26) demonstrated higher expression of MYC pathway genes (FDR q = 0.03) and lower expression of IFN-γ, IL-6/JAK/STAT3, and inflammatory pathway genes (FDR q < 0.001) compared to tumors from European American patients. TMPRSS2:ERG gene fusions were observed more frequently in tumors from European American compared to African American patients (41% vs. 11%, P = 0.015). Asian patients (N = 9) and other racial groups comprised a small minority of our cohort. No differences in overall survival were noted across racial groups. CONCLUSIONS: Despite demonstrating similar clinical outcomes, cancers from African Americans display distinct tumor biology. Specifically, we observed racial differences in expression of prostate cancer driver gene pathways (including potential clinically actionable pathways of IFN-γ and JAK/STAT) and DNA alterations, including TMPRSS2:ERG gene fusion. Our findings highlight the importance of racial diversity in future genomic profiling and clinical trials efforts.
引用
- Feng EM, Vo-Phamhi J, Subramanian AN, et al. Racial variation in the advanced prostate cancer genome. Prostate Cancer Prostatic Dis. 2025. PMID: 40164700. doi:10.1038/s41391-025-00949-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。